If you operate a behavioral health practice in Austin, you already know the demand for advanced depression care is outpacing supply. Adding Spravato to your practice is one of the most strategically sound moves an Austin-area operator can make right now. With a growing population, a high prevalence of treatment-resistant depression (TRD), and a limited number of certified treatment sites, the opportunity to serve an underserved patient population while building a differentiated service line is significant and immediate.
Why Austin's Demand for Spravato Is Surging
Austin has grown by nearly 30% over the past decade, making it one of the fastest-expanding metro areas in the United States. More residents means more people living with depression, and a meaningful subset of those patients will not respond adequately to standard antidepressant therapy. Nationally, estimates suggest that roughly one-third of people with major depressive disorder meet criteria for treatment-resistant depression.
That translates to tens of thousands of Austin-area residents who may qualify for Spravato (esketamine) nasal spray, which is FDA-approved for treatment-resistant depression in adults and represents a clinically distinct pathway for patients who have failed two or more adequate antidepressant trials. Despite this demand, the number of REMS-certified Spravato treatment sites in the Austin metro remains relatively small, creating a clear access gap that well-positioned practices can fill.
Psychiatrists, therapists, and referring primary care providers across Central Texas are actively looking for local partners who can accept these complex patients. Practices that establish a Spravato program early will capture referral relationships that tend to be sticky and long-lasting. For context on how regional behavioral health markets are evolving, our overview of mental health treatment expansion across Texas illustrates how similar dynamics are playing out in other major Texas metros.
Understanding REMS Certification and What It Actually Demands
Before a practice can administer Spravato, it must enroll in the FDA's Risk Evaluation and Mitigation Strategy (REMS) program. This is not a formality. Spravato must be administered under a REMS program in certified healthcare settings, and every patient must be monitored for at least two hours after each dose.
The REMS certification process requires your practice to designate a site coordinator, complete training modules, and attest to your ability to monitor patients for dissociation, sedation, and blood pressure changes during and after administration. Prescribers must also complete their own REMS enrollment separately from the site certification. The process is manageable, but it requires deliberate planning and dedicated staff time upfront.
The two-hour monitoring window is the most operationally significant constraint. As confirmed by peer-reviewed clinical literature on esketamine administration protocols, post-dose monitoring for at least two hours is non-negotiable and must occur in a certified healthcare setting. This means each patient visit occupies a clinical space for roughly two and a half to three hours when you factor in intake, administration, and discharge. Scheduling must be built around this reality from day one.
Space and Staffing Requirements for a Compliant Spravato Program
Running a Spravato program does not require a hospital or a large footprint, but it does require thoughtful space planning. At minimum, you need a private or semi-private room where the patient can self-administer the nasal spray under clinical supervision, a comfortable reclining chair or treatment chair, and monitoring equipment for blood pressure and pulse oximetry.
Most practices start with one to two dedicated treatment rooms and scale from there. A single treatment room running two to three patients per day, five days a week, can generate meaningful volume. However, you need to ensure the room is not being pulled double-duty for standard therapy sessions or psychiatric evaluations during Spravato hours, as the monitoring requirement makes the room unavailable for other uses during that window.
On the staffing side, you will need at least one clinician or trained clinical staff member present throughout each monitoring period. This is typically a nurse, medical assistant, or licensed clinical staff member who has completed REMS training. The supervising prescriber does not need to be physically present during the entire monitoring window at most sites, but must be available and accessible. Your REMS site coordinator will be responsible for maintaining compliance documentation, tracking patient enrollment, and managing supply chain logistics with your specialty pharmacy.
If your practice is already running an IOP or PHP, you may find that existing clinical staff can be cross-trained to support Spravato monitoring with relatively modest additional investment. Choosing the right EMR to document Spravato sessions, track monitoring vitals, and manage prior authorizations is also critical. A review of behavioral health EMR options for group practices can help you evaluate which platform best supports the documentation workflows a Spravato program requires.
Reimbursement and Billing Realities: What to Expect
Reimbursement is where many operators either get excited or get tripped up. The good news is that Spravato has established billing pathways. The drug itself is billed using a specific HCPCS J-code, and the administration and monitoring services are billed separately using evaluation and management or observation codes. Because Spravato cannot be dispensed for unsupervised home use, the entire episode of care occurs in your facility, which means you capture both the drug cost and the clinical service fee.
However, reimbursement realities are nuanced. Spravato billing involves payer-specific prior authorization requirements and reimbursement variability that can significantly affect your net revenue per session. Some commercial payers in Texas reimburse well; others require extensive prior authorization documentation, step therapy attestation, and periodic reauthorization. Medicare and Medicaid coverage policies vary and are evolving.
Before launching, conduct a payer mix analysis for your current patient population and the likely TRD referral population you will attract. Verify which of your contracted payers cover Spravato, what their prior authorization criteria look like, and whether your current contracts include favorable rates for in-office drug administration. Some practices negotiate a separate Spravato-specific contract or letter of agreement with payers to establish clear reimbursement terms before investing in the program infrastructure.
Cash-pay and self-pay pricing is also worth considering. Some patients, particularly those with high-deductible plans or payers that do not yet cover Spravato, will pay out of pocket. Having a transparent, competitive self-pay rate can expand your accessible patient pool and reduce your dependence on any single payer's coverage decisions.
How Spravato Complements Your Existing Service Lines
One of the strongest arguments for adding Spravato to your practice is how naturally it fits within an existing behavioral health continuum. Patients in IOP or PHP programs who are struggling with persistent depressive symptoms are often ideal Spravato candidates. Rather than losing those patients to a competing clinic or watching them disengage from treatment, you can offer an advanced intervention within your own walls.
Spravato also creates a structured touchpoint that keeps patients engaged with your practice over the induction period (typically twice weekly for four weeks) and the maintenance phase (weekly or biweekly for months). Each visit is an opportunity for a brief check-in, medication management, or coordination with a therapist. This kind of integrated care model improves outcomes and deepens the patient relationship.
From a referral development standpoint, becoming a certified Spravato site signals clinical sophistication to referring psychiatrists, primary care physicians, and other behavioral health providers. It positions your practice as a destination for complex patients rather than a generalist provider, which can elevate your reputation across the Austin metro referral network. This is particularly relevant as behavioral health practices across the country look to differentiate their service offerings, a dynamic we explore in our analysis of strategic growth opportunities in behavioral health markets.
Common Mistakes Operators Make When Launching a Spravato Program
The most common mistake is underestimating the operational lift of the two-hour monitoring requirement. Practices that try to fit Spravato patients into standard 45-minute appointment slots quickly run into scheduling conflicts, staff frustration, and compliance risk. Build your scheduling template around the monitoring window first, then work backward.
A second frequent error is launching without a clear prior authorization workflow. PA denials for Spravato are common on first submission, particularly if the documentation of prior antidepressant failures is incomplete or does not meet the payer's specific criteria. Invest in a PA specialist or work with a revenue cycle partner who has Spravato-specific experience before you see your first patient.
Third, some operators skip the payer contracting review and assume their existing behavioral health contracts cover Spravato administration. They do not always. A drug administered in-office under a REMS program may fall outside standard behavioral health benefit carve-outs and require separate authorization or contracting under a medical benefit. Clarify this before you invest in infrastructure.
Finally, do not neglect the patient experience design. Patients receiving Spravato are often in significant distress, having failed multiple prior treatments. The monitoring room environment, staff demeanor, and clinical communication style matter enormously for retention and outcomes. Practices that invest in a calm, supportive treatment environment see better patient adherence and stronger word-of-mouth referrals.
Evaluating ROI and Standing Up a Spravato Program in Austin
A practical ROI evaluation starts with your capacity assumptions. How many treatment rooms can you dedicate? How many sessions per room per day? What is your expected payer mix and average net reimbursement per session? From there, model your break-even volume and compare it to realistic patient acquisition projections based on your referral network and market.
Startup costs typically include REMS certification and training time, minor space modifications, monitoring equipment, EMR workflow configuration, and staff training. These are generally modest compared to the revenue potential of a well-run program. Many practices reach break-even within the first three to six months of operation at modest volume.
A phased approach works well for most practices. Start with one treatment room, one or two certified prescribers, and a small cohort of existing patients who meet TRD criteria. Use the first 90 days to refine your scheduling template, PA workflow, and clinical documentation before scaling. This limits risk and gives your team time to build confidence and competency before volume increases.
Practices looking to expand their service line portfolio more broadly, whether through organic growth or acquisition, will find that a Spravato program adds meaningful clinical and financial value to the overall practice profile. For operators considering multi-site growth in Texas, understanding the regional landscape, including how neighboring markets like those discussed in our look at behavioral health services across Texas metros, can inform site selection and expansion planning.
Frequently Asked Questions
How long does it take to get REMS-certified to offer Spravato in my Austin practice?
The REMS certification process for a new Spravato site typically takes two to four weeks from initial enrollment to approval, assuming all required documentation and training are completed promptly. Prescribers must complete their own separate REMS enrollment, which can run concurrently. The most common delays come from incomplete attestation forms or gaps in the designated site coordinator training. Planning for a four-to-six-week runway before your first patient visit is a reasonable and conservative approach.
What are the minimum space requirements to run a Spravato program?
You do not need a dedicated suite or large footprint to start. A single private or semi-private room with a comfortable reclining chair, blood pressure monitoring equipment, and pulse oximetry is sufficient for a one-room program. The room must be available for the full two-plus-hour monitoring window per patient visit, so it cannot be shared with other appointment types during that time. Most practices begin with one dedicated room and expand based on demand.
Which payers cover Spravato in Texas, and how difficult is prior authorization?
Coverage varies significantly by payer. Most major commercial insurers in Texas, including Blue Cross Blue Shield of Texas, Aetna, Cigna, and UnitedHealthcare, have Spravato coverage policies, but each has distinct prior authorization criteria that typically require documented failure of at least two adequate antidepressant trials. Medicare Part B covers Spravato for eligible beneficiaries under specific conditions. Medicaid coverage in Texas is more limited and evolving. Prior authorization denial rates are meaningful on first submission, so having a thorough PA process and clean documentation of prior treatment history is essential.
Can Spravato be integrated into an IOP or PHP program?
Yes, and this is one of the most clinically compelling use cases. Patients already enrolled in an IOP or PHP who are not responding adequately to standard pharmacotherapy can receive Spravato as an adjunct intervention within the same practice. The structured monitoring visits align naturally with the intensive outpatient schedule, and the clinical team already has the therapeutic relationship and documentation history needed to support prior authorization. Integration requires coordination between the Spravato prescriber and the IOP clinical team, but the workflow is manageable with clear protocols.
What is the typical revenue potential for a Spravato program in a behavioral health practice?
Revenue potential depends on payer mix, session volume, and your contracted reimbursement rates. A single treatment room running two to three patients per day at commercially insured rates can generate substantial monthly revenue, with net reimbursement per session varying by payer and contract terms. The induction phase (twice-weekly sessions for four weeks) followed by a maintenance phase creates a predictable, recurring revenue stream per patient. Most practices find that even modest volume, five to ten active patients per month, generates a meaningful contribution to practice revenue while building a referral base that grows over time.
Ready to Add Spravato to Your Austin Practice?
The window to establish your practice as a go-to Spravato provider in the Austin metro is open right now. Patient demand is real, certified sites are limited, and the operational requirements, while meaningful, are well within reach for a prepared behavioral health operator. The practices that move deliberately and build this service line correctly will be positioned to serve a growing population of TRD patients while strengthening their clinical reputation and referral network for years to come.
If you are evaluating whether adding Spravato to your practice makes sense for your specific situation, we would welcome the conversation. Reach out to our team to discuss your current service lines, patient population, and growth goals. We help behavioral health operators across Austin and Texas build sustainable, compliant, and financially sound clinical programs.
